Also trades as: 0K6R.L (LSE) · $vol 0M
NBIX NASDAQ
Neurocrine Biosciences, Inc.
1W: +2.9%
1M: +4.0%
3M: -19.2%
YTD: +3.9%
1Y: +1.4%
3Y: +32.3%
5Y: +41.6%
$146.00
+0.13 (+0.09%)
Weekly Expected Move ±3.9%
$131
$137
$143
$148
$154
Credit Risk of going bust: lower than 88% of companies Debt: 2.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.30 (down 99.8%), Neurocrine Biosciences, Inc. would be worth roughly what it owes.
Total debt $401.8M against a stock market value of $14.84B.
Distance to default 12.82 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $200.9M (short-term plus half of long-term), stock volatility 34.0%; Altman Z'' 4.79. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.30 (down 99.8%), Neurocrine Biosciences, Inc. would be worth roughly what it owes.
Total debt $401.8M against a stock market value of $14.84B.
Distance to default 12.82 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $200.9M (short-term plus half of long-term), stock volatility 34.0%; Altman Z'' 4.79. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships4
As Filer
counterparties named
4
As Counterparty
mentioned by others
1
Rel. Types
2021-11-22
Earliest Filing
2025-01-27
Latest Filing
partner: 4
Counterparties (Filed by NBIX)
4 relationshipsCompanies named in NBIX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited | TKPHF | partner | Amended and restated exclusive license agreement for osavampator development and commercialization rights. | 2025-01-27 | View |
| Voyager Therapeutics, Inc. | VYGR | partner | Strategic collaboration for development and commercialization of gene therapy programs including GBA1 and new CNS target | 2023-01-09 | View |
| Heptares Therapeutics Limited | — | partner | Entered into a Collaboration and License Agreement for the development and commercialization of sub-type selective musca | 2021-11-22 | View |
| Sosei Group Corporation | — | partner | Parent company of Heptares Therapeutics Limited, an affiliate involved in the collaboration. | 2021-11-22 | View |
Mentioned As Counterparty
4 mentionsOther companies that named NBIX in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| VYGR Voyager Therapeutics, Inc. | partner | Existing collaboration partner mentioned in the context of reimbursement for development costs. | 2024-01-02 | View |
| XENE Xenon Pharmaceuticals Inc. | partner | Collaboration to develop treatments for epilepsy, including exclusive license of NBI-921352. | 2023-08-09 | View |
| VTYX Ventyx Biosciences, Inc. | supplier | Sublessee of approximately 35,016 rentable square feet for Ventyx Biosciences' new corporate headquarters. | 2023-07-26 | View |
| VYGR Voyager Therapeutics, Inc. | partner | Entered into a Collaboration and License Agreement and Stock Purchase Agreement for gene therapy development and commerc | 2023-01-09 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-28 | Officer/Director Change | View | |
| 2026-07-31 | Exhibits | View | |
| 2026-07-30 | Earnings Release; Exhibits | View | |
| 2026-05-28 | Officer/Director Change; Shareholder Vote | View | |
| 2026-05-18 | Material Agreement; Acquisition/Disposition; Financial Obligation; Regulation FD; Exhibits | Agreement Acquisition | View |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-04-06 | Material Agreement; Exhibits | Agreement | View |
| 2026-02-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-24 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-10-28 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-30 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-05-22 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-04 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-02-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-27 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2024-12-20 | Other Events | View | |
| 2024-11-01 | Other Events | View | |
| 2024-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR